Saquinavir, the pioneer antiretroviral protease inhibitor

Bibliography

• UNAIDS. Report on the global HIV/AIDS epidemic, 2008. Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/GlobalReport/2008/2008_Global_report.asp. [Cited 23 March 2009]
   Google Scholar
• UNAIDS. What countries need, investments needed for 2010 targets. Available from: http://data.unaids.org/pub/Report/2009/20090210__investments_needed_2010_en.pdf. [Cited 23 March 2009]
   Google Scholar
• DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. November 3, 2008. Available from: http://AIDSinfo.nih.gov. [Cited 23 March 2009]
   Google Scholar
• De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009;33(4):307-20
   PubMed Web of Science ®Google Scholar
• HIV drugs in development. Available from: http://www.thebody.com/index/treat/newdrugs.html. [Cited 23 March 2009]
   Google Scholar
• Opravil M, Ledergerber B, Furrer H, et al. Clinical efficacy of early initiation of HAART in patients with asymptomatic HIV infection and CD4 cell count > 350 × 10(6) /l. Aids 2002;16(10):1371-81
   PubMed Web of Science ®Google Scholar
• Chene G, Sterne JA, May M, et al. Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies. Lancet 2003;362(9385):679-86
   PubMed Web of Science ®Google Scholar
• Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002;360(9327):119-29
   PubMed Web of Science ®Google Scholar
• Bittner B, Riek M, Holmes B, Grange S. Saquinavir 500 mg film-coated tablets demonstrate bioequivalence to saquinavir 200 mg hard capsules when boosted with twice-daily ritonavir in healthy volunteers. Antivir Ther 2005;10(7):803-10
   PubMed Web of Science ®Google Scholar
• Dear Dr letter, Roche Laboratories, Inc. Nutley, NJ, USA. May 2005
   Google Scholar
• Saquinavir product monograph. Roche Laboratories, Inc. Nutley, New Jersey, USA; 2007:32
   Google Scholar
• Cooper CL, van Heeswijk RP, Gallicano K, Cameron DW. A review of low-dose ritonavir in protease inhibitor combination therapy. Clin Infect Dis 2003;36(12):1585-92
   PubMed Web of Science ®Google Scholar
• Tremblay C, Merrill DP, Chou TC, Hirsch MS. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 isolates. J Acquir Immune Defic Syndr 1999;22(5):430-6
   PubMed Web of Science ®Google Scholar
• Robinson BS, Riccardi KA, Gong YF, et al. BMS-232632, a highly potent human immunodeficiency virus protease inhibitor that can be used in combination with other available antiretroviral agents. Antimicrob Agents Chemother 2000;44(8):2093-9
   PubMed Web of Science ®Google Scholar
• Dam E, Lebel-Binay S, Rochas S, et al. Synergistic inhibition of protease-inhibitor-resistant HIV type 1 by saquinavir in combination with atazanavir or lopinavir. Antivir Ther 2007;12(3):371-80
   PubMed Web of Science ®Google Scholar
• Johnson VA, Brun-Vezinet F, Clotet B, et al. Update of the drug resistance mutations in HIV-1. Top HIV Med 2008;16(5):138-45
   PubMedGoogle Scholar
• Autar RS, Ananworanich J, Apateerapong W, et al. Pharmacokinetic study of saquinavir hard gel caps/ritonavir in HIV-1-infected patients: 1600/100 mg once-daily compared with 2000/100 mg once-daily and 1000/100 mg twice-daily. J Antimicrob Chemother 2004;54(4):785-90
   PubMed Web of Science ®Google Scholar
• Boffito M, Dickinson L, Hill A, et al. Pharmacokinetics of once-daily saquinavir/ritonavir in HIV-infected subjects: comparison with the standard twice-daily regimen. Antivir Ther 2004;9(3):423-9
   PubMed Web of Science ®Google Scholar
• van der Lugt J, Gorowara M, Avihingsanon A, et al. A boosting-dose of 50 milligram of ritonavir generates adequate saquinavir plasma concentrations in Thai. 16th Conference on Retroviruses and Opportunistic Infections. Montreal, Canada 2009
   Google Scholar
• Fletcher CV, Jiang H, Brundage RC, et al. Sex-based differences in saquinavir pharmacology and virologic response in AIDS Clinical Trials Group Study 359. J Infect Dis 2004;189(7):1176-84
   PubMed Web of Science ®Google Scholar
• Pai MP, Schriever CA, Diaz-Linares M, et al. Sex-related differences in the pharmacokinetics of once-daily saquinavir soft-gelatin capsules boosted with low-dose ritonavir in patients infected with human immunodeficiency virus type 1. Pharmacotherapy 2004;24(5):592-9
   PubMed Web of Science ®Google Scholar
• Ribera E, Lopez RM, Diaz M, et al. Steady-state pharmacokinetics of a double-boosting regimen of saquinavir soft gel plus lopinavir plus minidose ritonavir in human immunodeficiency virus-infected adults. Antimicrob Agents Chemother 2004;48(11):4256-62
   PubMed Web of Science ®Google Scholar
• Robertson SM, Formentini E, Alfaro RM, et al. Lack of sex-related differences in saquinavir pharmacokinetics in an HIV-seronegative cohort. Br J Clin Pharmacol 2006;61(4):379-88
   PubMed Web of Science ®Google Scholar
• Autar RS, Wit FW, Sankote J, et al. Ketoconazole is inferior to ritonavir as an alternative booster for saquinavir in a once daily regimen in Thai HIV-1 infected patients. AIDS 2007;21(12):1535-9
   PubMed Web of Science ®Google Scholar
• Van der Lugt J, Molto J, Hawkins D, et al. Safety, efficacy and pharmacokinetics of saquinavir boosted by ritonavir (1000/100 mg BID) in pregnant HIV-infected women. 48th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington DC, US: American Society for Microbiology 2008
   Google Scholar
• Lonca M, Martinez-Rebollar M, Perez I, et al. Saquinavir 500 mg formulation + ritonavir (1000/100mg bid) in HIV+ pregnant women: Final results of a pilot pharmacokinetics study. 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands 2009
   Google Scholar
• von Hentig N, Nisius G, Lennemann T, et al. Pharmacokinetics, safety and efficacy of saquinavir/ ritonavir 1,000/100 mg twice daily as HIV type-1 therapy and transmission prophylaxis in pregnancy. Antivir Ther 2008;13(8):1039-46
   PubMed Web of Science ®Google Scholar
• Lopez-Cortes LF, Ruiz-Valderas R, Rivero A, et al. Efficacy of low-dose boosted saquinavir once daily plus nucleoside reverse transcriptase inhibitors in pregnant HIV-1-infected women with a therapeutic drug monitoring strategy. Ther Drug Monit 2007;29(2):171-6
   PubMed Web of Science ®Google Scholar
• Acosta EP, Bardeguez A, Zorrilla CD, et al. Pharmacokinetics of saquinavir plus low-dose ritonavir in human immunodeficiency virus-infected pregnant women. Antimicrob Agents Chemother 2004;48(2):430-6
   PubMed Web of Science ®Google Scholar
• Molto J, Llibre JM, Ribera E, et al. Saquinavir exposure in HIV-infected patients with chronic viral hepatitis. J Antimicrob Chemother 2009;63(5):992-7
   PubMed Web of Science ®Google Scholar
• Autar RS, Boffito M, Hassink E, et al. Interindividual variability of once-daily ritonavir boosted saquinavir pharmacokinetics in Thai and UK patients. J Antimicrob Chemother 2005;56(5):908-13
   PubMed Web of Science ®Google Scholar
• Frohlich M, Hoffmann MM, Burhenne J, et al. Association of the CYP3A5 A6986G (CYP3A5*3) polymorphism with saquinavir pharmacokinetics. Br J Clin Pharmacol 2004;58(4):443-4
   PubMed Web of Science ®Google Scholar
• Mouly SJ, Matheny C, Paine MF, et al. Variation in oral clearance of saquinavir is predicted by CYP3A5*1 genotype but not by enterocyte content of cytochrome P450 3A5. Clin Pharmacol Ther 2005;78(6):605-18
   PubMed Web of Science ®Google Scholar
• Josephson F, Allqvist A, Janabi M, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007;81(5):708-12
   PubMed Web of Science ®Google Scholar
• la Porte CJ, Li Y, Beique L, et al. The effect of ABCB1 polymorphism on the pharmacokinetics of saquinavir alone and in combination with ritonavir. Clin Pharmacol Ther 2007;82(4):389-95
   PubMed Web of Science ®Google Scholar
• Van der Lugt J, di Iulio J, Ananworanich J, et al. Allelic variants of the CYP3A4 and 5, ABCB1 and SLCO1B1 genes in a Thai HIV-infected population on saquinavir based antiretroviral regimen. 10th International Workshop on Clinical Pharmacology of HIV Therapy. Amsterdam, The Netherlands 2009
   Google Scholar
• Ritonavir, saquinavir combination–& warning. AIDS Treat News 1995;231:6
   Google Scholar
• Boffito M, Carriero P, Trentini L, et al. Pharmacokinetics of saquinavir co-administered with cimetidine. J Antimicrob Chemother 2002;50(6):1081-4
   PubMed Web of Science ®Google Scholar
• Kakuda TN, Falcon RW. Effect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteers. Pharmacotherapy 2006;26(8):1060-8
   PubMed Web of Science ®Google Scholar
• Winston A, Back D, Fletcher C, et al. Effect of omeprazole on the pharmacokinetics of saquinavir-500 mg formulation with ritonavir in healthy male and female volunteers. AIDS 2006;20(10):1401-6
   PubMed Web of Science ®Google Scholar
• Singh K, Dickinson L, Chaikan A, et al. Pharmacokinetics and safety of saquinavir/ritonavir and omeprazole in HIV-infected subjects. Clin Pharmacol Ther 2008;83(6):867-72
   PubMed Web of Science ®Google Scholar
• Beique L, Giguere P, la Porte C, Angel J. Interactions between protease inhibitors and acid-reducing agents: a systematic review. HIV Med 2007;8(6):335-45
   PubMed Web of Science ®Google Scholar
• Ribera E, Azuaje C, Lopez RM, et al. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J Antimicrob Chemother 2007;59(4):690-7
   PubMed Web of Science ®Google Scholar
• Rolla VC, da Silva Vieira MA, Pereira Pinto D, et al. Safety, efficacy and pharmacokinetics of ritonavir 400mg/saquinavir 400mg twice daily plus rifampicin combined therapy in HIV patients with tuberculosis. Clin Drug Investig 2006;26(8):469-79
   PubMed Web of Science ®Google Scholar
• Schmitt C, Riek M, Winters K, et al. Unexpected hepatotoxicity of rifampin and saquinavir/ritonavir in healthy male volunteers. Arch Drug Inf 2009;2(1):8-16
   PubMedGoogle Scholar
• Ribera E, Curran A. Double-boosted protease inhibitor antiretroviral regimens: what role? Drugs 2008;68(16):2257-67
   PubMed Web of Science ®Google Scholar
• King JR, Kakuda TN, Paul S, et al. Pharmacokinetics of saquinavir with atazanavir or low-dose ritonavir administered once daily (ASPIRE I) or twice daily (ASPIRE II) in seronegative volunteers. J Clin Pharmacol 2007;47(2):201-8
   PubMed Web of Science ®Google Scholar
• la Porte CJL, Wasmuth JC, Schneider K, et al. Lopinavir/ritonavir plus saquinavir in salvage therapy; pharmacokinetics, tolerability and efficacy. AIDS 2003;17(11):1700-2
   PubMed Web of Science ®Google Scholar
• Stephan C, Hentig N, Kourbeti I, et al. Saquinavir drug exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004;18(3):503-8
   PubMed Web of Science ®Google Scholar
• Boffito M, Kurowski M, Kruse G, et al. Atazanavir enhances saquinavir hard-gel concentrations in a ritonavir-boosted once-daily regimen. AIDS 2004;18(9):1291-7
   PubMed Web of Science ®Google Scholar
• Manosuthi W, Sungkanuparph S, Ruxrungtham K, et al. Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir. J Acquir Immune Defic Syndr 2008;47(1):127-9
   PubMed Web of Science ®Google Scholar
• von Hentig N, Muller A, Rottmann C, et al. Pharmacokinetics of saquinavir, atazanavir, and ritonavir in a twice-daily boosted double-protease inhibitor regimen. Antimicrob Agents Chemother 2007;51(4):1431-9
   PubMed Web of Science ®Google Scholar
• Winston A, Mallon PW, Satchell C, et al. The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation. Clin Infect Dis 2007;44(11):1475-83
   PubMed Web of Science ®Google Scholar
• Walmsley SL, Katlama C, Lazzarin A, et al. Pharmacokinetics, safety, and efficacy of tipranavir boosted with ritonavir alone or in combination with other boosted protease inhibitors as part of optimized combination antiretroviral therapy in highly treatment-experienced patients (BI Study 1182.51). J Acquir Immune Defic Syndr 2008;47(4):429-40
   PubMed Web of Science ®Google Scholar
• Boffito M, Dickinson L, Hill A, et al. Steady-State pharmacokinetics of saquinavir hard-gel/ritonavir/fosamprenavir in HIV-1-infected patients. J Acquir Immune Defic Syndr 2004;37(3):1376-84
   PubMed Web of Science ®Google Scholar
• Sekar VJ, Lefebvre E, Marien K, et al. Pharmacokinetic interaction between darunavir and saquinavir in HIV-negative volunteers. Ther Drug Monit 2007;29(6):795-801
   PubMed Web of Science ®Google Scholar
• Choi SO, Rezk NL, Kashuba AD. High-performance liquid chromatography assay for the determination of the HIV-protease inhibitor tipranavir in human plasma in combination with nine other antiretroviral medications. J Pharm Biomed Anal 2007;43(4):1562-7
   PubMed Web of Science ®Google Scholar
• Weller DR, Brundage RC, Balfour HH Jr, Vezina HE. An isocratic liquid chromatography method for determining HIV non-nucleoside reverse transcriptase inhibitor and protease inhibitor concentrations in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2007;848(2):369-73
   PubMed Web of Science ®Google Scholar
• Notari S, Bocedi A, Ippolito G, et al. Simultaneous determination of 16 anti-HIV drugs in human plasma by high-performance liquid chromatography. J Chromatogr B Analyt Technol Biomed Life Sci 2006;831(1-2):258-66
   PubMed Web of Science ®Google Scholar
• D'Avolio A, Baietto L, Siccardi M, et al. An HPLC-PDA method for the simultaneous quantification of the HIV integrase inhibitor raltegravir, the new nonnucleoside reverse transcriptase inhibitor etravirine, and 11 other antiretroviral agents in the plasma of HIV-infected patients. Ther Drug Monit 2008;30(6):662-9
   PubMed Web of Science ®Google Scholar
• Elens L, Veriter S, Di Fazio V, et al. Quantification of 8 HIV-protease inhibitors and 2 nonnucleoside reverse transcriptase inhibitors by ultra-performance liquid chromatography with diode array detection. Clin Chem 2009;55(1):170-4
   PubMed Web of Science ®Google Scholar
• ter Heine R, Alderden-Los CG, Rosing H, et al. Fast and simultaneous determination of darunavir and eleven other antiretroviral drugs for therapeutic drug monitoring: method development and validation for the determination of all currently approved HIV protease inhibitors and non-nucleoside reverse transcriptase inhibitors in human plasma by liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Rapid Commun Mass Spectrom 2007;21(15):2505-14
   PubMed Web of Science ®Google Scholar
• D'Avolio A, Siccardi M, Sciandra M, et al. HPLC-MS method for the simultaneous quantification of the new HIV protease inhibitor darunavir, and 11 other antiretroviral agents in plasma of HIV-infected patients. J Chromatogr B Analyt Technol Biomed Life Sci 2007;859(2):234-40
   PubMed Web of Science ®Google Scholar
• Dickinson L, Robinson L, Tjia J, et al. Simultaneous determination of HIV protease inhibitors amprenavir, atazanavir, indinavir, lopinavir, nelfinavir, ritonavir and saquinavir in human plasma by high-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2005;829(1-2):82-90
   PubMed Web of Science ®Google Scholar
• Fayet A, Beguin A, de Tejada BM, et al. Determination of unbound antiretroviral drug concentrations by a modified ultrafiltration method reveals high variability in the free fraction. Ther Drug Monit 2008;30(4):511-22
   PubMed Web of Science ®Google Scholar
• van Luin M, Kuks PF, Burger DM. Use of therapeutic drug monitoring in HIV disease. Curr Opin HIV AIDS 2008;3(3):266-71
   PubMed Web of Science ®Google Scholar
• la Porte C. Inhibitory quotient in HIV pharmacology. Curr Opin HIV AIDS 2008;3(3):283-7
   PubMed Web of Science ®Google Scholar
• Casado JL, Moreno A, Sabido R, et al. Individualizing salvage regimens: the inhibitory quotient (Ctrough/IC50) as predictor of virological response. AIDS 2003;17(2):262-4
   PubMed Web of Science ®Google Scholar
• Mallolas J, Blanco J, Labarga P, et al. Inhibitory quotient as a prognostic factor of response to a salvage antiretroviral therapy containing ritonavir-boosted saquinavir. The CIVSA Study. HIV Med 2007;8(4):226-33
   PubMed Web of Science ®Google Scholar
• Marcelin AG, Dalban C, Peytavin G, et al. Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients. Antimicrob Agents Chemother 2004;48(12):4687-92
   PubMed Web of Science ®Google Scholar
• Valer L, de Mendoza C, Soriano V. Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients. J Med Virol 2005;77(4):460-4
   PubMed Web of Science ®Google Scholar
• la Porte CJL, Back DJ, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 2006;3:4-14
   Google Scholar
• DHHS. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents; 3 November 2008
   Google Scholar
• Walmsley S, Avihingsanon A, Slim J, et al. Gemini: a noninferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults. J Acquir Immune Defic Syndr 2009;50(4):367-74
   PubMed Web of Science ®Google Scholar
• Dragsted UB, Gerstoft J, Youle M, et al. A randomized trial to evaluate lopinavir/ritonavir versus saquinavir/ritonavir in HIV-1-infected patients: the MaxCmin2 trial. Antivir Ther 2005;10(6):735-43
   PubMed Web of Science ®Google Scholar
• Dragsted UB, Gerstoft J, Pedersen C, et al. Randomized trial to evaluate indinavir/ritonavir versus saquinavir/ritonavir in human immunodeficiency virus type 1-infected patients: the MaxCmin1 Trial. J Infect Dis 2003;188(5):635-42
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Gayet-Ageron A, Ruxrungtham K, et al. Long-term efficacy and safety of first-line therapy with once-daily saquinavir/ritonavir. Antivir Ther 2008;13(3):375-80
   PubMed Web of Science ®Google Scholar
• Vrouenraets SME, Fernandez-Garcia E, Jackson A, et al. Saquinavir versus atazanavir once daily, each boosted with 100 mg ritonavir and combined with tenofovir/emtricitabine, result in comparable lipid changes after 24 weeks in treatment-naïve HIV infected patients [abstract P-32]. Antivir Ther 2008;13(Suppl 4):A46
   Google Scholar
• de Mendoza C, Valer L, Ribera E, et al. Performance of six different ritonavir-boosted protease inhibitor-based regimens in heavily antiretroviral-experienced HIV-infected patients. HIV Clin Trials 2006;7(4):163-71
   PubMed Web of Science ®Google Scholar
• Chetchotisakd P, Anunnatsiri S, Mootsikapun P, et al. Efficacy and tolerability of a double boosted protease inhibitor (lopinavir + saquinavir/ritonavir) regimen in HIV-infected patients who failed treatment with nonnucleoside reverse transcriptase inhibitors. HIV Med 2007;8(8):529-35
   PubMed Web of Science ®Google Scholar
• Staszewski S, Babacan E, Stephan C, et al. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy. J Antimicrob Chemother 2006;58(5):1024-30
   PubMed Web of Science ®Google Scholar
• Lotsch J, Harder S, Sturmer M, et al. Association of saquinavir plasma concentrations with side effects but not with antiretroviral outcome in patients infected with protease inhibitor-susceptible human immunodeficiency virus type 1. Antimicrob Agents Chemother 2007;51(9):3264-72
   PubMed Web of Science ®Google Scholar
• Stephan C, Carlebach A, Rottmann C, et al. Dose reduction effective in alleviating symptoms of saquinavir toxicity. Int J STD AIDS 2007;18(2):81-4
   PubMed Web of Science ®Google Scholar
• Grub S, Delora P, Ludin E, et al. Pharmacokinetics and pharmacodynamics of saquinavir in pediatric patients with human immunodeficiency virus infection. Clin Pharmacol Ther 2002;71(3):122-30
   PubMed Web of Science ®Google Scholar
• Ananworanich J, Kosalaraksa P, Hill A, et al. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr Infect Dis J 2005;24(10):874-9
   PubMed Web of Science ®Google Scholar
• Bunupuradah T, van der Lugt J, Kosalaraksa P, et al. Safety and efficacy of a double-boosted protease inhibitor combination, saquinavir and lopinavir/ritonavir, in pretreated children at 96 weeks. Antivir Ther 2009;14(2):241-8
   PubMed Web of Science ®Google Scholar
• Available from: www.clinicaltrials.govidentifierNCT00623597
   Google Scholar